Showing 321 - 340 results of 2,092 for search '"chemotherapy"', query time: 0.06s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324
  5. 325

    Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis by Ying Zhang, Xiao Zhou, Ran Xu, Guangcheng Luo, Xinjun Wang

    Published 2025-01-01
    “…Conclusion Our results suggest that the neutrophil-to-lymphocyte ratio may be a prognostic factor in patients with mCPRC with docetaxel-based chemotherapy.…”
    Get full text
    Article
  6. 326

    The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer by Ting Xu, Weili Xiong, Lili Zhang, Yuan Yuan

    Published 2024-01-01
    “…This study aimed to examine the efficacy and safety of anlotinib plus chemotherapy in HR+/HER2– MBC after progression on CDK4/6 inhibitors. …”
    Get full text
    Article
  7. 327
  8. 328
  9. 329
  10. 330

    Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis by Xiaojun Yang, Yihong Zeng, Qinquan Tan, Zhihua Huang, Jun Jia, Guanming Jiang

    Published 2022-01-01
    “…In the subgroup analysis, ICIs plus chemotherapy improved PFS (HR=0.60, 95%CI=0.40–0.80), but not OS (HR=0.75, 95%CI=0.30–1.19). …”
    Get full text
    Article
  11. 331

    The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma by Eko A. Pangarsa, Ridho M. Naibaho, Vina Yunarvika, Budi Setiawan, Damai Santosa, Catharina Suharti

    Published 2021-01-01
    “…Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. …”
    Get full text
    Article
  12. 332

    A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer by Danilo Giffoni de Mello Morais Mata, Rossanna C. Pezo, Kelvin K. W. Chan, Ines Menjak, Andrea Eisen, Maureen Trudeau

    Published 2024-12-01
    “…Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). …”
    Get full text
    Article
  13. 333

    Nomogram for prognosis prediction in metastatic pancreatic cancer patients undergoing intra-arterial infusion chemotherapy: incorporating immune-inflammation scores and coagulation indicators by Yifan Yang, Shaoqi Zong, Yongqiang Hua

    Published 2025-01-01
    “…Methods This study retrospectively analyzed the clinical data of 384 patients with MPC who underwent intra-arterial infusion chemotherapy (IAIC). Patients were randomly divided into training and validation cohorts. …”
    Get full text
    Article
  14. 334
  15. 335
  16. 336
  17. 337
  18. 338

    Enhanced Antitumor Immune Response in 2′-5′ Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy by Chan Kyu Sim, Jung Hoon Lee, In-Jeoung Baek, Sang-Wook Lee, Myeong Sup Lee

    Published 2019-01-01
    “…In this study, we investigated whether targeting or suppressing OASL1 could show synergistic effects on tumor clearance with conventional cancer therapies (such as chemotherapy and radiotherapy) using Oasl1−/− mice and a transplantable lung metastatic tumor cell model. …”
    Get full text
    Article
  19. 339

    Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis by Ya-Ni Zhang, Yu-Pei Chen, Pu-Yun OuYang, Tai-Xiang Lu, Fang-Yun Xie, Fei Han, Chun-Yan Chen

    Published 2025-01-01
    “…Synergistic effects have been observed when anti-programmed death-1 (PD-1) inhibitors are combined with chemotherapy or targeted therapy. Objectives: To compare the efficacy and safety of induction chemotherapy in combination with nimotuzumab with or without anti-PD-1 inhibitors for LANPC. …”
    Get full text
    Article
  20. 340